Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 10
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Megalencephalic leukoencephalopathy with subcortical cysts, A personal biochemical retrospective

  • Estévez, Raúl|||0000-0003-1579-650X
  • Elorza-Vidal, Xabier
  • Gaitan Peñas, Hector|||0000-0001-9797-903X
  • Pérez-Rius, Carla
  • Armand-Ugón, Mercedes|||0000-0002-4069-9915
  • Alonso-Gardón, Marta
  • Xicoy Espaulella, Efren
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Arnedo, Tanit
  • Capdevila-Nortes, Xavier
  • López-Hernández, Tania
  • Montolio, Marisol|||0000-0001-5494-5737
  • Duarri, Anna|||0000-0003-4075-5478
  • Teijido, Oscar|||0000-0002-4600-6972
  • Barrallo Gimeno, Alejandro|||0000-0003-2086-8926
  • Palacín Prieto, Manuel|||0000-0002-8670-293X
  • Nunes Martínez, Virginia|||0000-0002-5747-9310
Megalencephalic leukoencephalopathy with subcortical cysts (MLC) is a rare type of leukodystrophy characterized by dysfunction of the role of glial cells in controlling brain fluid and ion homeostasis. Patients affected by MLC present macrocephaly, cysts and white matter vacuolation, which lead to motor and cognitive impairments. To date, there is no treatment for MLC, only supportive care. MLC is caused by mutations in the MLC1 and GLIALCAM genes. MLC1 is a membrane protein with low identity to the Kv1.1 potassium channel and GlialCAM belongs to an adhesion molecule family. Both proteins form a complex with an as-yet-unknown function that is expressed mainly in the astrocytes surrounding the blood-brain barrier and in Bergmann glia. GlialCAM also acts as an auxiliary subunit of the chloride channel ClC-2, thus regulating its localization at cell-cell junctions and modifying its functional properties by affecting the common gate of ClC-2. Recent studies in Mlc1-, GlialCAM- and Clcn2-knockout mice or Mlc1-knockout zebrafish have provided fresh insight into the pathophysiology of MLC and further details about the molecular interactions between these three proteins. Additional studies have shown that GlialCAM/MLC1 also regulates other ion channels (TRPV4, VRAC) or transporters (Na+/K+-ATPase) in a not-understood manner. Furthermore, it has been shown that GlialCAM/MLC1 may influence signal transduction mechanisms, thereby affecting other proteins not related with transport such as the EGF receptor. Here, we offer a personal biochemical retrospective of the work that has been performed to gain knowledge of the pathophysiology of MLC, and we discuss future strategies that may be used to identify therapeutic solutions for MLC patients.
Repisalud
Publication Artículo de revisión (ReviewArticle)

Evaluation of the recombinant protein -TSP-2 for the serological diagnosis of imported urogenital schistosomiasis and comparison with commercially available tests

  • Luzón-García, María Pilar
  • Navarro, Laura
  • Rodríguez, Esther
  • Soriano-Pérez, Manuel Jesús
  • Vázquez-Villegas, José
  • Cabeza-Barrera, María Isabel
  • Loukas, Alex
  • Castillo-Fernández, Nerea
  • Perteguer-Prieto, Maria Jesus
  • Sotillo, Javier
  • Salas-Coronas, Joaquin
Different agencies have emphasized the need to evaluate current serological methods for screening patients with suspected urogenital schistosomiasis. However, there is still a lack of evidence regarding the most appropriate methods for this purpose. Here we assessed the diagnostic efficacy of a newly developed serological technique that utilizes the recombinant protein -TSP-2, applied to the urine and serum of migrants suspected of having urogenital schistosomiasis. The sensitivity, specificity, positive and negative predictive values of an in-house enzyme-linked immunosorbent assay (ELISA) using the recombinant protein -TSP-2 were analysed and compared with other commercial serological methods. Due to the limitations of microscopy as a perfect reference method, a latent class analysis (LCA) and composite reference standard (CRS) approach was used to determine the sensitivity and specificity of each test. According to the LCA model, the commercial tests NovaLisa and immunochromatography test (ICT) immunoglobulin G–immunoglobulin M (IgG–IgM) presented the highest sensitivity (100%), whereas the -TSP-2 serum ELISA test had 79.2%. The -TSP-2 urine and serum ELISA tests had the highest specificities among the serological methods (87.5 and 75%, respectively). CRS modelling showed that the ICT IgG–IgM, NovaLisa and -TSP-2 serum tests led in sensitivity at 97.1, 88.6 and 71.4%, respectively, with all tests except that the ICT IgG–IgM test having a specificity >90%. -TSP-2 has been validated as a screening tool for patients suspected of having urogenital schistosomiasis. Although commercial serological tests have shown higher sensitivities, -TSP-2 could be valuable for confirming results from tests with lower specificity. Nevertheless, further studies with larger patient cohorts are necessary to fully verify its potential.
RiuNet. Repositorio Institucional de la Universitat Politécnica de Valéncia
Publication Artículo de revisión (ReviewArticle)

Measurement of energy resolution with the NEXT-White silicon photomultipliers

  • Contreras, T.
  • Palmeiro, B.
  • Almazán, H.
  • Para, A.
  • Martinez-Lema, G.
  • Guenette, R.
  • Adams, C.
  • Aparicio, B.
  • Aranburu, A. I.
  • Arazi, L.
  • Arnquist, I.J.
  • Auria-Luna, F.
  • Ayet, S.
  • Azevedo, C.D.R.
  • Álvarez-Puerta, Vicente|||0000-0001-6938-8259
  • Ballester Merelo, Francisco José|||0000-0002-2464-5116
  • Esteve Bosch, Raul|||0000-0002-1289-6938
  • Herrero Bosch, Vicente|||0000-0003-0860-2789
  • Mora Mas, Francisco José|||0000-0003-2281-9546
  • Toledo Alarcón, José Francisco|||0000-0002-9782-4510
[EN] The NEXT-White detector, a high-pressure gaseous xenon time projection chamber, demonstrated the excellence of this technology for future neutrinoless double beta decay searches using photomultiplier tubes (PMTs) to measure energy and silicon photomultipliers (SiPMs) to extract topology information. This analysis uses 83mKr data from the NEXT-White detector to measure and understand the energy resolution that can be obtained with the SiPMs, rather than with PMTs. The energy resolution obtained of (10.9±0.6)%, full-width half-maximum, is slightly larger than predicted based on the photon statistics resulting from very low light detection coverage of the SiPM plane in the NEXT-White detector. The difference in the predicted and measured resolution is attributed to poor corrections, which are expected to be improved with larger statistics. Furthermore, the JHEP09(2024)112 noise of the SiPMs is shown to not be a dominant factor in the energy resolution and may be negligible when noise subtraction is applied appropriately, for high-energy events or larger SiPM coverage detectors. These results, which are extrapolated to estimate the response of large coverage SiPM planes, are promising for the development of future, SiPM-only, readout planes that can offer imaging and achieve similar energy resolution to that previously demonstrated with PMTs., The NEXT Collaboration acknowledges support from the following agencies and institutions: the European Research Council (ERC) under Grant Agreement No. 951281-BOLD; the European Union’s Framework Programme for Research and Innovation, Horizon 2020 (2014–2020), under Grant Agreement No. 957202-HIDDEN; Spain’s MCIN/AEI and the ERDF (“A way of making Europe”) under grants PID2021-125475NB and the Severo Ochoa Programme grant CEX2018-000867-S; the Generalitat Valenciana (Spain) under grants PROMETEO/2021/087 and CIDEGENT/2019/049; the Department of Education of the Basque Government (Spain) under the predoctoral training programme for non-doctoral research personnel; the “la Caixa” Foundation (ID 100010434) under fellowship code LCF/BQ/PI22/11910019; the Portuguese Foundation for Science and Technology (FCT) under project UID/FIS/04559/2020 supporting the activities of LIBPhys-UC; the Israel Science Foundation (ISF) under grant 1223/21; the Pazy Foundation (Israel) under grants 310/22, 315/19, and 465; the U.S. Department of Energy under contract numbers DE-AC02-06CH11357 (Argonne National Laboratory), DE-AC02-07CH11359 (Fermi National Accelerator Laboratory), DE-FG02-13ER42020 (Texas A&M), DE-SC0019054 (The University of Texas at Arlington), and DE-SC0019223 (The University of Texas at Arlington); the U.S. National Science Foundation under award NSF CHE-2004111; and the Robert A. Welch Foundation under award Y-2031-20200401. Finally, we are grateful to the Laboratorio Subterráneo de Canfranc for hosting and supporting the NEXT experiment.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Bacterial-mediated Selenium Nanoparticles as Highly Selective Antimicrobial Agents with Anticancer Properties

  • Medina Cruz, David
  • Truong, Linh B.
  • Sotelo, Eduardo
  • Martínez Orellana, Lidia
  • González Sagardoy, María Ujué
  • Huttel, Yves
  • Webster, Thomas J.
  • García-Martín, José Miguel
  • Cholula-Díaz, Jorge L.
The green synthesis of nanomaterials offers advantages over traditional chemical methods, such as the production of biocompatible nanostructures in an environmentally friendly and cost-effective manner. Among all of the available green synthesis routes, the use of bacteria offers a high-throughput and versatile synthesis of nanoparticles that can be used in a wide range of biomedical approaches. In this article, we present a controllable and versatile synthesis of selenium nanoparticles (SeNPs) using bacterial isolates of both Gram negative and Gram positive bacteria. The SeNPs were characterized in terms of their physicochemical properties and tested in both antimicrobial and cytotoxicity assays, showing a selective dose-dependent antibacterial activity in a selected range of concentrations (especially when SeNPs synthesized by a particular bacterial isolate were exposed to that isolate) and a mild cytotoxicity when exposed to human dermal fibroblasts. Furthermore, the SeNPs were tested for their anticancer activity by exposure to melanoma cells (skin cancer) in in vitro models, showing a significant dose¿response cytotoxic behavior that was associated to the production of reactive oxygen species. Therefore, this work presents a robust and versatile method to produce SeNPs using selected bacterial isolates for numerous biomedical applications., The authors from Tecnologico de Monterrey and CSIC thank the bilateral project BILTC22001 for funding. The authors from Tecnologico de Monterrey also thank the Department of Sciences – Chemistry and Nanotechnology at Tecnologico de Monterrey, campus Monterrey. TJW thanks Art Zaropoulo for funding. The authors acknowledge the service from the MiNa Laboratory at IMN, funded from CM (project SpaceTec, S2018/ NMT-4291 TEC2SPACE), MINECO (project CSIC13-4E-1794), and EU (FEDER, FSE)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Bibliometric Overview on T-Cell Intracellular Antigens and Their Pathological Implications

  • Ramos-Velasco, Beatriz
  • Naranjo, Rocío
  • Izquierdo, José M.
T-cell intracellular antigen 1 (TIA1) and TIA1-like/related protein (TIAL1/TIAR) are two members of the classical family of RNA binding proteins. Through their selective interactions with distinct RNAs and proteins, these multifunctional regulators are involved in chromatin remodeling, RNA splicing and processing and translation regulation, linking them to a wide range of diseases including neuronal disorders, cancer and other pathologies. From their discovery to the present day, many studies have focused on the behavior of these proteins in order to understand their impact on molecular and cellular processes and to understand their relationship to human pathologies. The volume of research on these proteins in various fields, including molecular biology, biochemistry, cell biology, immunology and cancer, has steadily increased, indicating a growing interest in these gene expression regulators among researchers. This information can be used to know the most productive institutions working in the field, understand the focus of research, identify key areas of involvement, delve deeper into their relationship and impact on different diseases, and to establish the level of study associated with them., B.R.V. and R.N.S. were supported by Garantía Juvenil (GARJUVCAM-2020; Ref. 37722) and INVESTIGO-2022 (Ref. EICS24211028C098/13-2022-008566) programs of the Community of Madrid, respectively. Research in our laboratory is supported by the Ministerio de Ciencia e Innovación and Agencia Española de Investigación through FEDER funds (PID2021-126152OB-100) (MICINN/AEI/FEDER, UE). The CBMSO receives an institutional grant from Fundación Ramón Areces., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Renal Biopsy in Type 2 Diabetic Patients

  • Espinel Garuz, Eugenia
  • Agraz Pamplona, Irene|||0000-0002-4223-6834
  • Ibernon, Meritxell
  • Ramos Terrades, Natalia|||0000-0001-9832-326X
  • Fort Ros, Joan
  • Seron, Daniel|||0000-0003-2054-653X
The majority of diabetic patients with renal involvement are not biopsied. Studies evaluating histological findings in renal biopsies performed in diabetic patients have shown that approximately one third of the cases will show pure diabetic nephropathy, one third a non-diabetic condition and another third will show diabetic nephropathy with a superimposed disease. Early diagnosis of treatable non-diabetic diseases in diabetic patients is important to ameliorate renal prognosis. The publication of the International Consensus Document for the classification of type 1 and type 2 diabetes has provided common criteria for the classification of diabetic nephropathy and its utility to stratify risk for renal failure has already been demonstrated in different retrospective studies. The availability of new drugs with the potential to modify the natural history of diabetic nephropathy has raised the question whether renal biopsies may allow a better design of clinical trials aimed to delay the progression of chronic kidney disease in diabetic patients.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Prevalence of prenatal exposure to substances of abuse, questionnaire versus biomarkers

  • Chiandetti, Antonella
  • Hernandez, Gimena|||0000-0001-5319-3465
  • Mercadal-Hally, Maria|||0000-0003-1687-6448
  • Alvarez, Airam
  • Andreu-Fernandez, Vicente|||0000-0001-7183-8706
  • Navarro-Tapia, Elisabet
  • Bastons-Compta, Adriana
  • Garcia-Algar, Oscar|||0000-0001-5708-4362
Alcohol and drugs of abuse consumption in young adults, including women of childbearing age, has experienced significant increase over the past two decades. The use of questionnaires as the only measure to investigate prenatal alcohol and drugs of abuse exposure underestimates the real prevalence of exposure and could mislead to wrong conclusions. Therefore, the aim of this article was to compare reported rates of prenatal alcohol and drugs of abuse consumption with biomarkers of exposure by a comprehensive review of the available literature. We searched MEDLINE and EMBASE databases for articles catalogued between 1992 and 2015. We identified relevant published studies that assessed the comparison between prenatal exposure to alcohol and drugs of abuse assessed by self-reported questionnaire of consumption versus biomarkers of exposure. Thirteen studies were included regarding alcohol consumption, and seven of them about drugs of abuse. Women who admitted consumption during pregnancy by questionnaire varied from 0 to 37% for alcohol, from 0 to 4.3% for cocaine, and 2.9% for tetrahydrocannabinol (THC). Positive biomarkers results ranged from 16 to 44% for alcohol, 15.4% for cocaine, and from 4 to 12.4% for THC. Biomarkers should always complement questionnaires, as it has been shown that self-report may underestimate prenatal exposure to substances of abuse.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Pathophysiological Underpinnings of Extra-Motor Neurodegeneration in Amyotrophic Lateral Sclerosis, New Insights From Biomarker Studies

  • Reyes-Leiva, David|||0000-0001-6983-7130
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Cortés-Vicente, Elena|||0000-0002-1428-1072
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Luna Salva, Noemí de|||0000-0002-4342-794X
  • Blesa, Rafael|||0000-0003-4026-2884
  • Belbin, Olivia|||0000-0002-6109-6371
  • Montal, Victor|||0000-0002-5714-9282
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
Amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) lie at opposing ends of a clinical, genetic, and neuropathological continuum. In the last decade, it has become clear that cognitive and behavioral changes in patients with ALS are more frequent than previously recognized. Significantly, these non-motor features can impact the diagnosis, prognosis, and management of ALS. Partially overlapping neuropathological staging systems have been proposed to describe the distribution of TAR DNA-binding protein 43 (TDP-43) aggregates outside the corticospinal tract. However, the relationship between TDP-43 inclusions and neurodegeneration is not absolute and other pathophysiological processes, such as neuroinflammation (with a prominent role of microglia), cortical hyperexcitability, and synaptic dysfunction also play a central role in ALS pathophysiology. In the last decade, imaging and biofluid biomarker studies have revealed important insights into the pathophysiological underpinnings of extra-motor neurodegeneration in the ALS-FTLD continuum. In this review, we first summarize the clinical and pathophysiological correlates of extra-motor neurodegeneration in ALS. Next, we discuss the diagnostic and prognostic value of biomarkers in ALS and their potential to characterize extra-motor neurodegeneration. Finally, we debate about how biomarkers could improve the diagnosis and classification of ALS. Emerging imaging biomarkers of extra-motor neurodegeneration that enable the monitoring of disease progression are particularly promising. In addition, a growing arsenal of biofluid biomarkers linked to neurodegeneration and neuroinflammation are improving the diagnostic accuracy and identification of patients with a faster progression rate. The development and validation of biomarkers that detect the pathological aggregates of TDP-43 in vivo are notably expected to further elucidate the pathophysiological underpinnings of extra-motor neurodegeneration in ALS. Novel biomarkers tracking the different aspects of ALS pathophysiology are paving the way to precision medicine approaches in the ALS-FTLD continuum. These are essential steps to improve the diagnosis and staging of ALS and the design of clinical trials testing novel disease-modifying treatments.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Absence of antibodies against KIR4.1 in multiple sclerosis, A three-technique approach and systematic review

  • Navas Madroñal, Miquel|||0000-0003-2984-1471
  • Valero-Mut, Ana
  • Martinez-Zapata, Mª José|||0000-0002-5836-1138
  • Simón Talero, Manuel J.
  • Figueroa, Sebastián
  • Vidal-Fernández, Núria|||0009-0008-3749-6448
  • López-Góngora, Mariana
  • Escartín Siquier, Antonio E.
  • Querol, Luis|||0000-0002-4289-8264
Antibodies targeting the inward-rectifying potassium channel KIR4.1 have been associated with multiple sclerosis (MS) but studies using diverse techniques have failed to replicate this association. The detection of these antibodies is challenging; KIR4.1 glycosylation patterns and the use of diverse technical approaches may account for the disparity of results. We aimed to replicate the association using three different approaches to overcome the technical limitations of a single technique. We also performed a systematic review to examine the association of anti-KIR4.1 antibodies with MS. Serum samples from patients with MS (n = 108) and controls (n = 77) were tested for the presence of anti-KIR4.1 antibodies using three methods: 1) by ELISA with the low-glycosylated fraction of recombinant KIR4.1 purified from transfected HEK293 cells according to original protocols; 2) by immunocytochemistry using KIR4.1-transfected HEK293 cells; and 3) by immunocytochemistry using the KIR4.1.-transfected MO3.13 oligodendrocyte cell line. We developed a systematic review and meta-analysis of the association of anti-KIR4.1 antibodies with MS according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We did not detect anti-KIR4.1 antibodies in the MS patients or in controls using ELISA. Neither did we detect any significant reactivity against the antigen on the cell surface using the KIR4.1-transfected HEK293 cells or the KIR4.1-transfected MO3.13 cells. We included 13 prospective controlled studies in the systematic review. Only three studies showed a positive association between anti-KIR4.1 and MS. Clinical and statistical heterogeneity between studies precluded meta-analysis of their results. We found no association between anti-KIR4.1 antibody positivity and MS. Although this lack of replication may be due to technical limitations, evidence from our study and others is mounting against the role of KIR4.1 as a relevant MS autoantigen.
Dipòsit Digital de Documents de la UAB
Publication Artículo de revisión (ReviewArticle)

Cardiovascular Disease in Type 1 Diabetes Mellitus, Epidemiology and Management of Cardiovascular Risk

  • Colom, Cristina|||0000-0002-2926-4697
  • Rull, Anna|||0000-0002-8907-7754
  • Sánchez Quesada, José Luis|||0000-0003-0224-591X
  • Pérez, Antonio|||0000-0001-5528-1143
Cardiovascular disease (CVD) is a major cause of mortality in type 1 diabetes mellitus (T1DM) patients, and cardiovascular risk (CVR) remains high even in T1DM patients with good metabolic control. The underlying mechanisms remain poorly understood and known risk factors seem to operate differently in T1DM and type 2 diabetes mellitus (T2DM) patients. However, evidence of cardiovascular risk assessment and management in T1DM patients often is extrapolated from studies on T2DM patients or the general population. In this review, we examine the existing literature about the prevalence of clinical and subclinical CVD, as well as current knowledge about potential risk factors involved in the development and progression of atherosclerosis in T1DM patients. We also discuss current approaches to the stratification and therapeutic management of CVR in T1DM patients. Chronic hyperglycemia plays an important role, but it is likely that other potential factors are involved in increased atherosclerosis and CVD in T1DM patients. Evidence on the estimation of 10-year and lifetime risk of CVD, as well as the efficiency and age at which current cardiovascular medications should be initiated in young T1DM patients, is very limited and clearly insufficient to establish evidence-based therapeutic approaches to CVD management.